The parties have entered a non-binding Letter of Intent
Inspira Technologies collaborates with a leading Israeli medical centre for clinical evaluation of INSPIRA ART device. (Credit: Chokniti Khongchum from Pixabay)
Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA ART100 device (“Device) within Shamir Medical Center’s clinical environment. This includes evaluating the device’s fit with the hospital’s clinical needs, efficiency in workflow, and overall impact on healthcare delivery. The hospital will procure all required disposables for operating the Devices as part of the LOI. Inspira will gain access to device operation data and user experience in a real-life clinical setting. The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel. The progression of this LOI hinges on the AMAR (medical devices and accessories) approval by the Israeli Ministry of Health for the Device, and the subsequent formalization of a detailed definitive evaluation agreement between the parties.
Joe Hayon, President of Inspira Technologies, stated: “With the anticipated U.S. Food and Drug Administration (FDA) approval on the horizon, I am confident that this prospective collaboration with Shamir Medical Center will enhance the efficacy of life-support care and establish a pathway for its adoption in both local and international markets.”
Source: Company Press Release